Refametinib
Refametinib, also known as RDEA119, BAY 86-9766, is an orally bioavailable, selective MEK inhibitor with potential anti-tumor activity. The MEK inhibitor RDEA119 specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), thereby inhibiting growth factor-mediated cell signaling and tumor cell proliferation.
| Supplier | Alfa Cytology |
|---|---|
| Product # | BC0558 |
| Pricing | 10.0 mg, 25.0 mg, 50.0 mg, 100.0 mg, 200.0 mg, 500.0 mg, 1.0 g, 2.0 g, inquire |